Drug interactions with solid tumour-targeted therapies
- 1 January 2014
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 89 (1), 179-196
- https://doi.org/10.1016/j.critrevonc.2013.08.007
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancerCancer Chemotherapy and Pharmacology, 2011
- Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinomaCancer, 2011
- Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancerBreast Cancer Research and Treatment, 2011
- Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsCancer Chemotherapy and Pharmacology, 2010
- Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumorsInvestigational New Drugs, 2010
- Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2010
- Marginal increase of sunitinib exposure by grapefruit juiceCancer Chemotherapy and Pharmacology, 2010
- Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation studyCancer Chemotherapy and Pharmacology, 2009
- Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancerInvestigational New Drugs, 2009
- Effect of antacid on imatinib absorptionCancer Chemotherapy and Pharmacology, 2008